Real life evaluation of safinamide effectiveness in Parkinson’s disease

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations

(2017) Anthony H. V. Schapira et al.   JAMA Neurology

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide

(2016) Fabrizio Stocchi et al.   Drug Design Development and Therapy

Safinamide: First Global Approval

(2015) Emma D. Deeks   DRUGS

Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis

(2015) Carlo Cattaneo et al.   Journal of Parkinsons Disease

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

(2014) R. Cilia et al.   BRAIN

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

(2013) Rupam Borgohain et al.   MOVEMENT DISORDERS

Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease

(2012) Dénes Zádori et al.   JOURNAL OF NEURAL TRANSMISSION

Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies

(2011) Claudia Binda et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

An expert opinion on safinamide in Parkinson's disease

(2008) Marco Onofrj et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS